These 3 Stocks Have Crushed the Market, and the Next 10 Years Could Be Even Better

The article argues that Costco, Intuitive Surgical, and Visa can justify premium valuations through durable growth runways and strong competitive moats. Costco is highlighted as trading at about 50x forward earnings with low-double-digit earnings growth and ~13% average annual dividend growth over five years; Intuitive Surgical trades near 45x forward earnings with expected 12% to 14% annual earnings growth in 2026-2027; Visa trades at 23.5x forward earnings with low-double-digit earnings growth and nearly 15% average dividend growth over the past five years. Overall tone is constructive but largely opinion-driven, with limited near-term price impact.

Analysis

The common thread across COST, ISRG, and V is not just “quality” but self-funding network effects that make valuation compression less likely than it appears. Each business has a reinvestment loop that is hard for smaller rivals to copy: COST can monetize loyalty through membership renewal and modest fee hikes, ISRG can deepen switching costs via surgeon training and installed-base utilization, and V can ride the migration from cash to digital rails without needing consumer behavior to change all at once. The second-order implication is that these are not pure multiple stocks; they are compounding franchises where unit economics can remain resilient even if broader consumer or healthcare growth slows.

The most interesting competitive takeaway is that the biggest threat is not direct substitution but time-to-scale. In retail, competitors may match prices, but they struggle to replicate traffic density and fee-funded margins; in medtech, a cyber event or reimbursement pushback can delay procedure growth, but it is unlikely to alter the adoption curve; in payments, stablecoin rhetoric matters more as a narrative overhang than as an immediate cash-flow problem. That means near-term drawdowns, if they occur, should be treated as volatility events rather than thesis breaks unless you see evidence of member churn, procedure deferrals, or transaction-share loss.

The risk/reward is most attractive where the market is discounting the least disruptive path. Visa looks cheapest on a growth-adjusted basis and could re-rate if the market stops pricing in a structural payments reset; Costco is the most defensible but already most fully owned, so upside likely comes from steady earnings compounding rather than multiple expansion; Intuitive has the cleanest long-duration runway but also the most sensitivity to scrutiny around utilization and capital equipment spending. The contrarian view is that the market may be overestimating how quickly “disruption” arrives in all three names; in practice, these businesses usually lose share only after years of underappreciated entrenchment, not quarters.

Key Decisions for Investors

• Add to V on 1-3 month weakness; target a 12-18 month hold. Risk/reward favors a re-rating from low-20s forward earnings toward historic mid-20s if payments growth stays low-double-digit.
• Buy COST only on pullbacks of 5-8% from prior highs; 12-month upside is lower than V but drawdown risk is also lower. Use it as a quality compounder rather than a momentum trade.
• Maintain/ initiate a long ISRG position but prefer staged entry over 2-4 weeks due to headline risk. If procedure growth remains intact, the stock can support a premium multiple; if not, downside is likely limited to a digestion phase rather than a thesis break.
• Pair trade: long V / short MA on a 6-12 month horizon if you want the cleaner valuation gap with similar secular exposure. V has more room for multiple expansion from current levels, while the fundamental delta should remain modest.
• Sell short-dated downside puts on COST or V rather than chasing upside outright; both names have favorable long-term profiles but near-term expected returns are more asymmetric on the downside after strong runs.